Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
Research Spotlight
  • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL

    September 2019

  • New Prognostic System for Patients with Relapsed Follicular Lymphoma

    May 2018

  • Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT

    May 2018

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Hodgkin Lymphoma
  • Email
  • Print This Page

Related Resources

  • HCT Guidelines App
  • Subscribe to the Latest Research
  • All Outcomes and Trends Data

Patient Resources

  • Transplant Outcomes and Treatment Decisions
  • Transplant and Hodgkin Lymphoma (PDF)
  • Transplant Basics Booklet
  • Transplant Basics Videos

Hodgkin Lymphoma

Approximately 8,200 individuals are diagnosed with Hodgkin lymphoma each year in the United States. Hodgkin lymphoma is most frequently diagnosed among people aged 20-34 years. [1]

Advances

Significant progress has been made in the treatment of patients with Hodgkin lymphoma, with cure rates of 80% or higher using chemotherapeutic approaches. [2] New active agents (e.g., bendamustine and brentuximab) have been introduced that can help control relapsed or refractory Hodgkin lymphoma in order to allow procession to transplant. [3,4]

An accurate assessment of the stage of disease in patients with Hodgkin lymphoma is critical for the selection of the appropriate therapy. [5] Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease. [6]

Hematopoietic cell transplantation (HCT), often autologous but occasionally allogeneic, can be used for recurrent disease. Allogeneic HCT in patients with relapsed/refractory Hodgkin lymphoma has significantly improved over time. A recent single-center study found that 3-year progression-free survival after allogeneic HCT improved from 23% in 2000-2008 to 49% in 2009-2013. The corresponding 3-year overall survival increased from 50% to 84%. [7]

Outcomes

Review outcomes for allogeneic and autologous HCT in patients with Hodgkin lymphoma below. View additional Hodgkin Lymphoma slides showing demographic data and transplant trends.

Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program.


Figure 1: Hodgkin Lymphoma Survival, Unrelated HCT

Hodgkin Lymphoma Survival, Unrelated HCT

Download slide "Hodgkin Lymphoma Survival, Unrelated HCT"

Figure 2. Hodgkin Lymphoma Survival, Autologous HCT, by Disease Status

Hodgkin Lymphoma Survival, Autologous HCT, by Disease Status

Download slide "Hodgkin Lymphoma Survival, Autologous HCT, by Disease Status" 

Figure 3. Hodgkin Lymphoma Survival, Allogeneic HCT, by Donor Type

Hodgkin Lymphoma Survival, Allogeneic HCT, by Donor Type

Download slide "Hodgkin Lymphoma Survival, Allogeneic HCT, by Donor Type" 

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [8]

Transplant Consultation Guidelines: Hodgkin Lymphoma

  • Primary induction failure
  • First relapse
  • CR2 or subsequent relapse

Download as a slide
View complete Referral Timing Guidelines

References

  1. SEER Stat Fact Sheets: Hodgkin Lymphoma. Website accessed 2 November, 2017. Access
  2. National Comprehensive Cancer Network (NCCN) Guidelines: Hodgkin Lymphoma, version 2.2013; page MS-2. Access
  3. Moscowitz AJ. Novel agents in Hodgkin lymphoma. Curr Oncol Rep. 2012; 14(5): 419-423. Access
  4. Zinzani PL, Derenzini E, Pellegrini C, et al. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Br J Haematol. 2013; 163(5): 681-683. Access
  5. Perales M-A, Ceberio I, Armand P, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(6): 971-983. Access
  6. Ansell, SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012; 87(12): 1096-1103. Access
  7. Hegerova L, Cao Q, Lazaryan A, et al. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant. 2017; 52(5): 697-703. Access
  8. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright